These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 25682546)

  • 1. Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements.
    Park S; Park TS; Choi CM; Lee DH; Kim SW; Lee JS; Kim WS; Song JS; Lee JC
    Clin Lung Cancer; 2015 Sep; 16(5):e83-9. PubMed ID: 25682546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.
    Chen YF; Hsieh MS; Wu SG; Chang YL; Yu CJ; Yang JC; Yang PC; Shih JY
    J Thorac Oncol; 2016 Jul; 11(7):1140-52. PubMed ID: 27094798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.
    Camidge DR; Kono SA; Lu X; Okuyama S; Barón AE; Oton AB; Davies AM; Varella-Garcia M; Franklin W; Doebele RC
    J Thorac Oncol; 2011 Apr; 6(4):774-80. PubMed ID: 21336183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients with ROS1 rearrangement-positive non-small-cell lung cancer benefit from pemetrexed-based chemotherapy.
    Song Z; Su H; Zhang Y
    Cancer Med; 2016 Oct; 5(10):2688-2693. PubMed ID: 27544536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
    Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
    BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
    Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC
    Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA 25, microRNA 145, and microRNA 210 as biomarkers for predicting the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who are negative for epidermal growth factor receptor mutations or anaplastic lymphoma kinase translocations.
    Shi SB; Wang M; Tian J; Li R; Chang CX; Qi JL
    Transl Res; 2016 Apr; 170():1-7. PubMed ID: 26687391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer.
    Liang Y; Wakelee HA; Neal JW
    Clin Lung Cancer; 2015 Sep; 16(5):366-73. PubMed ID: 25665893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.
    Drilon A; Bergagnini I; Delasos L; Sabari J; Woo KM; Plodkowski A; Wang L; Hellmann MD; Joubert P; Sima CS; Smith R; Somwar R; Rekhtman N; Ladanyi M; Riely GJ; Kris MG
    Ann Oncol; 2016 Jul; 27(7):1286-91. PubMed ID: 27056998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
    Li W; Zhang Z; Guo L; Qiu T; Ling Y; Cao J; Guo H; Zhao H; Li L; Ying J
    Oncotarget; 2016 Feb; 7(7):8332-40. PubMed ID: 26789109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
    Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
    Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
    Lou NN; Zhang XC; Chen HJ; Zhou Q; Yan LX; Xie Z; Su J; Chen ZH; Tu HY; Yan HH; Wang Z; Xu CR; Jiang BY; Wang BC; Bai XY; Zhong WZ; Wu YL; Yang JJ
    Oncotarget; 2016 Oct; 7(40):65185-65195. PubMed ID: 27533086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer.
    Lee JO; Kim TM; Lee SH; Kim DW; Kim S; Jeon YK; Chung DH; Kim WH; Kim YT; Yang SC; Kim YW; Heo DS; Bang YJ
    J Thorac Oncol; 2011 Sep; 6(9):1474-80. PubMed ID: 21642865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect.
    Sahnane N; Frattini M; Bernasconi B; Zappa F; Schiavone G; Wannesson L; Antonelli P; Balzarini P; Sessa F; Mazzucchelli L; Tibiletti MG; Martin V
    Clin Lung Cancer; 2016 Jan; 17(1):56-61. PubMed ID: 26381283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
    Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
    Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
    de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
    Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status.
    Wang J; Dong Y; Cai Y; Zhou L; Wu S; Liu G; Su D; Li X; Qin N; Nong J; Jia H; Zhang Q; Mu J; Zeng X; Zhang H; Zhang S; Zhang Z
    J Cancer Res Clin Oncol; 2014 Mar; 140(3):453-60. PubMed ID: 24442099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement].
    Caliez J; Monnet I; Pujals A; Rousseau-Bussac G; Jabot L; Boudjemaa A; Leroy K; Chouaid C
    Rev Mal Respir; 2017 May; 34(5):576-580. PubMed ID: 27646667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.
    Ulivi P; Chiadini E; Dazzi C; Dubini A; Costantini M; Medri L; Puccetti M; Capelli L; Calistri D; Verlicchi A; Gamboni A; Papi M; Mariotti M; De Luigi N; Scarpi E; Bravaccini S; Turolla GM; Amadori D; Crinò L; Delmonte A
    Clin Lung Cancer; 2016 Sep; 17(5):384-390. PubMed ID: 26712101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma.
    Sun JM; Lira M; Pandya K; Choi YL; Ahn JS; Mao M; Han J; Park K; Ahn MJ; Kim J
    Lung Cancer; 2014 Feb; 83(2):259-64. PubMed ID: 24300132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.